September 29, 2022
Video
C diff patients live in fear of a recurrence, says gastroenterologist Paul Feuerstadt, MD. RBX2660 has entered the FDA pipeline and looks to end this vicious cycle.
Article
A European panel of experts endorsed the FDA’s recommendations.
September 28, 2022
Drs Chopra and Feuerstadt summarize challenges with current treatments and discuss live biotherapeutic products that are being studied for recurrent C difficile infection (rCDI).
Dr Lodise summarizes foundational trials that led to the use of fecal microbiota transplant for the treatment of rCDI.
September 27, 2022
A fecal microbiota transplant (FMT) trial was halted early due to clear evidence the treatment was superior to placebo.
September 22, 2022
The Vaccines and Related Biological Products Advisory Committee's (VRBPAC) positive vote follows the committee’s review of the data from the biologics license application (BLA) for RBX2660.
September 21, 2022
Dr Teena Chopra shares her approach to monitoring patients with C difficile infection (CDI).
Drs Tom Lodise and Bincy Abraham provide an overview of fecal microbiota transplantation and long-term safety of FMT use.
September 20, 2022
Bifidobacterium and Bacteroides in the gut microbiome are important to vaccine responsiveness and could be used in vaccine adjuvants in the future, a recent review shows.
September 16, 2022
Compared to fidaxomicin and vancomycinfecal, microbiota transplant (FMT) was the most cost-effective treatment for first and subsequent recurrent C difficile infection.
CDC Finds Recovery Common From Rare Vaccine-Related Myocarditis
September's Top 5 Infectious Disease Stories
COVID-19 Vaccine Boosters: Roadblocks, the Future, and Communicating the Benefits to Patients
CDC Updates Pneumococcal Conjugate Vaccine Recommendations
